During the last session, Profound Medical Corp (NASDAQ:PROF)’s traded shares were 0.41 million, with the beta value of the company hitting 0.65. At the end of the trading day, the stock’s price was $6.05, reflecting an intraday loss of -2.26% or -$0.14. The 52-week high for the PROF share is $11.42, that puts it down -88.76 from that peak though still a striking 6.94% gain since the share price plummeted to a 52-week low of $5.63. The company’s market capitalization is $181.74M, and the average intraday trading volume over the past 10 days was 84800.0 shares, and the average trade volume was 70.32K shares over the past three months.
Profound Medical Corp (PROF) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PROF has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.28.
Profound Medical Corp (NASDAQ:PROF) trade information
Profound Medical Corp (PROF) registered a -2.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.26% in intraday trading to $6.05, hitting a weekly high. The stock’s 5-day price performance is -11.16%, and it has moved by -15.38% in 30 days. Based on these gigs, the overall price performance for the year is -25.77%. The short interest in Profound Medical Corp (NASDAQ:PROF) is 0.49 million shares and it means that shorts have 6.77 day(s) to cover.
The consensus price target of analysts on Wall Street is $17, which implies an increase of 64.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $17 and $17 respectively. As a result, PROF is trading at a discount of -180.99% off the target high and -180.99% off the low.
Profound Medical Corp (PROF) estimates and forecasts
In the rating firms’ projections, revenue will increase 71.18% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.78M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 5.79M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.61M and 2.01M respectively. In this case, analysts expect current quarter sales to grow by 82.87% and then jump by 188.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.91%. While earnings are projected to return 4.02% in 2025, the next five years will return 14.91% per annum.
PROF Dividends
Profound Medical Corp is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Profound Medical Corp (NASDAQ:PROF)’s Major holders
Profound Medical Corp insiders own 7.94% of total outstanding shares while institutional holders control 50.52%, with the float percentage being 54.88%. GAGNON SECURITIES LLC is the largest shareholder of the company, while 66.0 institutions own stock in it. As of 2024-06-30, the company held over 1.51 million shares (or 6.209% of all shares), a total value of $12.66 million in shares.
The next largest institutional holding, with 1.5 million shares, is of FIL LTD’s that is approximately 6.1945% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.75 million.
Also, the Mutual Funds coming in first place with the largest holdings of Profound Medical Corp (PROF) shares are ROYCE MICRO-CAP TRUST, INC. and ROYCE FUND-Royce Micro-Cap Fund . Data provided on Dec 31, 2024 indicates that ROYCE MICRO-CAP TRUST, INC. owns about 427.97 shares. This amounts to just over 1.42 percent of the company’s overall shares, with a $2.59 million market value. The same data shows that the other fund manager holds slightly less at 233.46, or about 0.78% of the stock, which is worth about $1.41 million.
